EntryPoint Capital LLC Acquires 55,382 Shares of LifeStance Health Group, Inc. $LFST

Key Points

• EntryPoint Capital LLC increased its holdings in LifeStance Health Group by 171.9%, buying 55,382 additional shares, bringing its total to 87,591 shares valued at $583,000.
• LifeStance Health Group reported an earnings per share of ($0.01) for the last quarter, surpassing analysts’ expectations and showing a 10.6% increase in revenue year-over-year.
• Analysts have a consensus rating of "Moderate Buy" for LifeStance Health Group, with a target price range between $8.00 and $9.00 from various brokerages.

EntryPoint Capital LLC increased its stake in LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) by 171.9% during the first quarter, according to its most recent filing with the SEC. The fund owned 87,591 shares of the company's stock after buying an additional 55,382 shares during the quarter. EntryPoint Capital LLC's holdings in LifeStance Health Group were worth $583,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. DekaBank Deutsche Girozentrale purchased a new position in shares of LifeStance Health Group in the 1st quarter worth about $31,000. Xponance Inc. purchased a new position in shares of LifeStance Health Group in the 1st quarter worth about $69,000. Ameriprise Financial Inc. purchased a new position in shares of LifeStance Health Group in the 4th quarter worth about $87,000. Kapitalo Investimentos Ltda purchased a new position in shares of LifeStance Health Group in the 1st quarter worth about $87,000. Finally, Forum Financial Management LP purchased a new stake in LifeStance Health Group during the fourth quarter valued at about $110,000. 85.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on LFST. Wall Street Zen raised shares of LifeStance Health Group from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. BTIG Research began coverage on shares of LifeStance Health Group in a report on Friday, July 25th. They set a "buy" rating and a $8.00 price objective on the stock. Finally, UBS Group upped their price target on LifeStance Health Group from $8.50 to $9.00 and gave the company a "buy" rating in a research report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, LifeStance Health Group has an average rating of "Moderate Buy" and a consensus target price of $8.50.

LifeStance Health Group Trading Up 0.9%

NASDAQ:LFST traded up $0.05 during trading hours on Friday, hitting $5.55. The company had a trading volume of 3,284,657 shares, compared to its average volume of 3,180,084. The company has a market capitalization of $2.16 billion, a PE ratio of -111.00 and a beta of 1.13. The stock has a 50-day moving average price of $4.67 and a 200 day moving average price of $6.01. LifeStance Health Group, Inc. has a 52 week low of $3.74 and a 52 week high of $8.61. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.48 and a quick ratio of 1.48.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.03) by $0.02. LifeStance Health Group had a negative net margin of 1.23% and a negative return on equity of 1.11%. The firm had revenue of $345.31 million for the quarter, compared to analysts' expectations of $345.05 million. During the same quarter in the previous year, the business posted ($0.06) EPS. The company's quarterly revenue was up 10.6% on a year-over-year basis. LifeStance Health Group has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities research analysts predict that LifeStance Health Group, Inc. will post -0.18 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder Summit Partners L. P sold 8,407,643 shares of the business's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $5.07, for a total transaction of $42,626,750.01. Following the completion of the transaction, the insider directly owned 33,524,715 shares in the company, valued at approximately $169,970,305.05. The trade was a 20.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Ujjwal Ramtekkar sold 16,000 shares of the business's stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $5.94, for a total value of $95,040.00. Following the transaction, the insider owned 113,435 shares of the company's stock, valued at approximately $673,803.90. This trade represents a 12.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 20,423,643 shares of company stock worth $103,561,790 in the last 90 days. Corporate insiders own 3.20% of the company's stock.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.